Timothy Eugene Sullivan, Chief Financial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 13,258 shares at $89.41 ($1.2M) on 2023-07-03, disclosed to the SEC on 2023-07-06.
Scheduled sale ($1.2M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $89.41 | 3,192 | $285K | 23.9% |
| 2 | $89.41 | 3,192 | $285K | 23.9% |
| 3 | $90.42 | 3,287 | $297K | 24.9% |
| 4 | $90.42 | 3,287 | $297K | 24.9% |
| 5 | $91.10 | 300 | $27K | 2.3% |
| Total | $89.95 avg | 13,258 |
| $1.2M |
| 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $86K | — | Filing → |
| APLS | SELL | 2025-10-23 | $280K | — | Filing → |
| APLS | SELL | 2025-09-10 | $2.1M | — | Filing → |